中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Original Research Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

文献类型：期刊论文

作者He, Wen-Zhuo8; Huang, Yu-Hua7; Hu, Wan-Ming7; Wang, Fang6; Xu, Yu-Xia5; Yi, Jia-Hong8; Xue, Ju8; Yang, Yuan-Zhong7; Chao, Xiao-Ying3,4; Lin, Han-Bin1,2,3
刊名EUROPEAN JOURNAL OF CANCER
出版日期2023-11-01
卷号194页码:9
ISSN号0959-8049
关键词Epstein-Barr virus Intrahepatic cholangiocarcinoma Programmed cell death protein 1 Immunotherapy
DOI10.1016/j.ejca.2023.113337
通讯作者Lin, Han-Bin(linhanbin@simm.ac.cn) ; Guo, Gui-Fang(guogf@sysucc.org.cn) ; Yun, Jing-Ping(yunjp@sysucc.org.cn) ; Xia, Liang-Ping(xialp@sysucc.org.cn)
英文摘要Aim: Epstein-Barr virus-associated intrahepatic cholangiocarcinoma (EBVaICC) has a distinct genomic profile and increased CD3+ and CD8+ T cells infiltration. However, the efficacy of immunotherapy in EBVaICC remains largely unknown. This study aimed to assess the efficacy of programmed cell death protein 1 (PD-1) antibody therapy in EBVaICC. Methods: Patients with metastatic biliary tract cancer (BTC) diagnosed at Sun Yat-sen University Cancer Center from January 2016 to December 2021 were identified. In situ hybridisation was performed to detect EBV. Overall survival (OS) and progression-free survival (PFS) were measured. Results: A total of 698 patients with metastatic BTC were identified, of whom 39 (5.6%) had EBVaICC. Among the 136 patients who were not administered PD-1 antibody, the OS was similar between patients with EBVaICC and EBV-negative ICC (median OS 12.5 versus 9.5 months, respectively; P = 0.692). For the 205 patients who were administered PD-1 antibody, patients with EBVaICC had significantly longer OS than patients with EBV-negative ICC (median OS 24.9 versus 11.9 months, respectively; P = 0.004). Seventeen patients with EBVaICC were administered PD-1 antibody. Eight patients (47%) achieved a partial response, and 17 patients achieved disease control. The median PFS was 17.5 months. Conclusions: This study identified a clinically actionable subset of patients with EBVaICC with a promising response to the PD-1 antibody. (c) 2023 Elsevier Ltd. All rights reserved.
WOS关键词MISMATCH-REPAIR ; CLINICOPATHOLOGICAL FEATURES ; SOLID TUMORS ; EXPRESSION
WOS研究方向Oncology
语种英语
出版者ELSEVIER SCI LTD
WOS记录号WOS:001094908000001
源URL[http://119.78.100.183/handle/2S10ELR8/307748]  
专题中国科学院上海药物研究所
通讯作者Lin, Han-Bin; Guo, Gui-Fang; Yun, Jing-Ping; Xia, Liang-Ping
作者单位1.SSIP Healthcare & Med Demonstrat Zone, Zhongshan 528400, Guangdong, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
3.Chinese Acad Sci, Zhongshan Inst Drug Discovery, SIMM, Zhongshan, Guangdong, Peoples R China
4.Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanning, Guangxi, Peoples R China
5.Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China
7.Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China
8.Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, VIP Reg,Canc Ctr, Guangzhou, Guangdong, Peoples R China
推荐引用方式
GB/T 7714		 He, Wen-Zhuo,Huang, Yu-Hua,Hu, Wan-Ming,et al. Original Research Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma[J]. EUROPEAN JOURNAL OF CANCER,2023,194:9.
APA He, Wen-Zhuo.,Huang, Yu-Hua.,Hu, Wan-Ming.,Wang, Fang.,Xu, Yu-Xia.,...&Xia, Liang-Ping.(2023).Original Research Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.EUROPEAN JOURNAL OF CANCER,194,9.
MLA He, Wen-Zhuo,et al."Original Research Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma".EUROPEAN JOURNAL OF CANCER 194(2023):9.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。